NORTON WATERFORD
PharmaNORTON WATERFORD is a pharmaceutical company focused on Respiratory. Key products include QVAR REDIHALER.
NORTON WATERFORD's Key Drugs
NORTON WATERFORD's core commercial portfolio centers on QVAR REDIHALER, spanning Respiratory — its most strategically important drugs approved in the last 15 years.
NORTON WATERFORD's Recent FDA Approvals
New NDA/BLA approvals for NORTON WATERFORD over the last two years — novel drugs only, excluding generics and label supplements.
NORTON WATERFORD's Therapeutic Areas
NORTON WATERFORD's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NORTON WATERFORD's Top Competitors
NORTON WATERFORD's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NORTON WATERFORD Pipeline Snapshot
Active clinical trials for NORTON WATERFORD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • QVAR REDIHALER leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-08-03
- Latest
- 2025-09-26
- Applications
- 1